Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis | Zendy

Teclegiorgis Gebremariam | Zendy; Sondus Alkhazraji | Zendy; Yiyou Gu | Zendy; Shakti Singh | Zendy; Abdullah Alqarihi | Zendy; Karen Joy Shaw | Zendy; Ashraf S. Ibrahim | Zendy

Open Access

Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis

Author(s) -

Teclegiorgis Gebremariam,

Sondus Alkhazraji,

Yiyou Gu,

Shakti Singh,

Abdullah Alqarihi,

Karen Joy Shaw,

Ashraf S. Ibrahim

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01966-19

Subject(s) - galactomannan , posaconazole , aspergillosis , pulmonary aspergillosis , biomarker , lung , placebo , medicine , pharmacology , microbiology and biotechnology , immunology , voriconazole , biology , pathology , antifungal , biochemistry , alternative medicine

Galactomannan (GM) detection in biological samples has been shown to predict therapeutic response by azoles and polyenes. In a murine invasive pulmonary aspergillosis model, fosmanogepix or posaconazole treatment resulted in an ∼6- to 7-log reduction in conidial equivalents (CE)/g lung tissue after 96 h versus placebo. Changes in GM levels in BAL fluid and serum mirrored reductions in lung CE, with significant decreases seen after 96 h or 72 h for fosmanogepix or posaconazole, respectively ( P < 0.02).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research